Enac plus Hexal

Quick links to important sections

Enac plus Hexal

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Enac plus Hexal

Quick Facts

Property Description
Active Ingredients Enalapril maleate, Hydrochlorothiazide
Form Oral Tablet
Pharmacological Class Antihypertensive Agent; ACE Inhibitor/Diuretic Combination
General Purpose Management of Essential Hypertension
Origin Synthetic

What Type of Medicine is Enac plus Hexal?

Enac plus Hexal is a prescription-only pharmaceutical drug delivered as an oral tablet and classified as an antihypertensive agent. It is specifically manufactured as a fixed-dose combination (FDC) product, meaning it contains two different active compounds in a single dosage unit. The antihypertensive classification confirms its established therapeutic role in managing elevated blood pressure.

Enalapril and Hydrochlorothiazide: The Dual Composition

The medicine's composition is defined by its two entirely synthetic active ingredients: Enalapril maleate and Hydrochlorothiazide (HCT). Enalapril maleate belongs to the class of Angiotensin-Converting Enzyme (ACE) Inhibitors, and Hydrochlorothiazide is categorized as a Thiazide Diuretic. Both ingredients are compounded with solid pharmaceutical excipients to form the final oral tablet.

This dual composition is clinically recognized for providing a comprehensive approach to pressure management, offering a therapeutic solution for adults whose hypertension is not adequately controlled by a single medication. The synthetic origin and FDC structure are supported by pharmacological studies demonstrating the rationale for combining an ACE Inhibitor with a Diuretic for enhanced blood pressure control.

General Purpose: Treating Essential Hypertension

The general purpose of this combined preparation is the effective management of essential hypertension, or chronic high blood pressure. The combination provides a synergistic effect by simultaneously addressing two factors that contribute to high blood pressure: the tension in blood vessel walls and the volume of fluid in the bloodstream. This function is vital for reducing the long-term strain on the heart and arteries associated with uncontrolled high blood pressure, leading to better cardiovascular outcomes.

Regulatory References

  1. Enalapril Maleate and Hydrochlorothiazide Tablets, USP - DailyMed

What side effects are possible with Enac plus Hexal?

Possible Side Effects and Safety Information

The safety profile for the fixed-dose combination of Enalapril (an ACE inhibitor) and Hydrochlorothiazide (a thiazide diuretic) is structured by official regulatory documents into classifications based on frequency and affected system. All listed effects are documented adverse reactions derived from clinical data and post-marketing surveillance.


Frequency-Classified Adverse Reactions

Adverse reactions are officially categorized by their documented incidence:

  • Very Common: Dizziness and headache are the most frequently reported effects.
  • Common: Adverse reactions classified as common include cough, fatigue, weakness (asthenia), hypotension, nausea, diarrhoea, and certain electrolyte imbalances such as hypokalaemia.
  • Uncommon to Rare: Less common events cover a wide range of system-organ classes, including gastrointestinal disturbances, skin reactions, and nervous system effects. The most serious adverse reactions, such as angioedema (swelling of the face, limbs, lips, tongue, or larynx), acute renal failure, and hepatic failure, are classified as rare but are explicitly noted in regulatory safety information.

Safety Constraints and Population Notes

The regulatory labeling defines strict safety constraints (contraindications) and specific population notes:

  • The medicine is contraindicated in individuals with a history of ACE inhibitor-related angioedema and in those with severe organ impairment, specifically severe hepatic impairment, anuria, and severe renal impairment (creatinine clearance <30 mL/min).
  • The medication is also generally contraindicated during the second and third trimesters of pregnancy due to the risk of fetal toxicity.
  • Time-related safety patterns note that hypotension and dizziness are reported as more frequently observed at the start of treatment or during initial dose increases.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for an overdose of this combined medication (Enalapril maleate and Hydrochlorothiazide) is defined by severe cardiovascular and fluid disturbances. Documented manifestations include profound hypotension (a severe drop in blood pressure), tachycardia, and palpitations. Signs of acute overexposure also involve excessive diuresis and fluid depletion, leading to severe electrolyte disturbances such as hypokalemia and hyponatremia. Central nervous system effects such as somnolence and stupor are also documented presentations.

Severe or life-threatening outcomes officially documented in regulatory labeling include the development of circulatory shock secondary to profound hypotension and the onset of acute renal failure. Overdose is noted as a particular concern for elderly patients due to the increased risk of poor blood flow to critical organs.

Immediate medical attention must be sought for any suspected overdose. Contact emergency services immediately if the patient has collapsed, is having trouble breathing, or cannot be awakened. Officially described management procedures are symptomatic and supportive treatment, which includes intravenous infusion of normal saline solution to counteract hypotension and correction of electrolyte imbalance. No specific pharmacological antidote is known for this combination product, although the active metabolite Enalaprilat is dialyzable.

Therapeutic Uses of Enac plus Hexal

Quick Facts: Main Uses

  • Support for managing high blood pressure (hypertension).
  • Assists in reducing the risk of cardiovascular events.
  • Used as part of a strategy to maintain blood pressure within a target range.

Enac plus Hexal is a medication prescribed to assist in the management of high blood pressure, a condition also known as hypertension. Maintaining blood pressure in an appropriate range is a critical component of a comprehensive health strategy and helps to mitigate potential complications associated with elevated pressure levels.

This agent is utilized to support the reduction of blood pressure by combining two established therapeutic approaches. By achieving and sustaining lower blood pressure, this medication may contribute to reducing the risk of serious cardiovascular events, such as heart attack and stroke. It may also support kidney health by lessening the impact of sustained hypertension on these organs.

For most individuals, Enac plus Hexal is not typically prescribed as a first-line therapy but is instead used in cases where other single-agent treatments have not achieved the desired blood pressure goals. It is an available option in the long-term treatment plan to help patients maintain circulatory stability and support overall heart function.

Eligibility and Restrictions for Use

Who Can and Cannot Use Enac plus Hexal?

The population eligibility for Enac plus Hexal (Enalapril/Hydrochlorothiazide) is strictly defined by regulatory documents, distinguishing between approved use, conditional use, and absolute contraindications.

Populations for Whom Use is Established

Use of this combination medicine is established for adults with essential hypertension, particularly those whose blood pressure is not adequately controlled by enalapril monotherapy alone. While older adults are generally permitted to use the drug, caution is advised due to the higher prevalence of reduced organ function in this age group.

Absolute Contraindications (Must Not Use)

The medicine is prohibited for several populations due to high risk:

  • Patients with a history of angioedema related to any previous use of an ACE inhibitor, or those with hereditary/idiopathic angioedema.
  • Individuals with known allergy to sulfonamide-derived drugs (due to the hydrochlorothiazide component) or to any ingredient in the tablet.
  • Use is contraindicated in the second and third trimesters of pregnancy.
  • Patients with severe organ dysfunction, including anuria (inability to pass urine), severe renal impairment (creatinine clearance le 30 mL/min), or severe hepatic impairment.
  • Patients concurrently taking Sacubitril/Valsartan or those with diabetes or renal impairment taking Aliskiren.

Restricted or Non-Recommended Populations

  • Pediatric Population: The medicine is not recommended for children and adolescents, as its safety and efficacy have not been formally established in this age group.
  • First Trimester Pregnancy/Lactation: Use is not recommended during the first trimester of pregnancy or while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for Enalapril/Hydrochlorothiazide (Enac plus Hexal) strictly based on government regulatory labeling.

Contraindicated Combinations and Restrictions

Co-administration with Neprilysin Inhibitors (e.g., Sacubitril-containing products) is formally prohibited and requires a 36-hour separation period to avoid the risk of angioedema. Aliskiren-containing products are contraindicated in patients with Diabetes Mellitus or with moderate-to-severe Renal Impairment (GFR less than 60 mL/min/1.73 m^2). This restriction addresses the documented risk of severe hyperkalemia and renal dysfunction resulting from dual RAAS blockade.

Clinically Significant Interactions

Interacting Agent/Substance Official Interaction Outcome Classification
Potassium Supplements, K-Sparing Diuretics Increased risk of hyperkalemia (high serum potassium levels).
Lithium Reduced renal clearance of lithium, leading to a high risk of lithium toxicity.
NSAIDs (e.g., Ibuprofen) Reduced antihypertensive effect and increased risk of worsening renal function.
Cholestyramine/Colestipol Resins Reduced absorption of the Hydrochlorothiazide component.
Alcohol, Barbiturates, Narcotics Documented potentiation of orthostatic hypotension (dizziness upon standing).

Interactions involving antidiabetic agents (e.g., Insulin) may necessitate a dosage adjustment of the antidiabetic agent, as stated in regulatory documents. Caution is noted for patients with Hepatic Impairment, as minor electrolyte changes from the diuretic component may officially precipitate hepatic coma.

Mechanism of Action

How Enac plus Hexal Works

Enac plus Hexal is a combination that acts on the physiological cascade and modulates multiple relevant biological pathways.


Angiotensin-Converting Enzyme Inhibition

One component, the Angiotensin-Converting Enzyme (ACE) inhibitor, acts as a competitive antagonist, binding to the ACE active site. This inhibition decreases the enzymatic conversion of Angiotensin I to the potent vasoconstrictor Angiotensin II within the Renin-Angiotensin-Aldosterone System (RAAS) cascade.


Thiazide Diuretic Action on Renal Tubules

The second component, a thiazide diuretic, exerts its action by binding to the Na^+- Cl^- cotransporter on the luminal membrane of the distal convoluted tubule. This binding inhibits the reabsorption of Na^+ and Cl^- ions, increasing their concentration in the tubular fluid and subsequently increasing their excretion via the urine.


Systemic Physiological Consequence

The synergistic action of both compounds, by simultaneously modulating the RAAS cascade and increasing renal Na^+ and water clearance, affects systemic physiological function.

Dosage and Administration Information

How to Use Enac plus Hexal

This section outlines the general principles for the administration of the fixed-dose combination of Enalapril Maleate and Hydrochlorothiazide (HCT).


Administration Overview

Feature Usage Principle
Route and Form Administered via the oral route as a fixed-dose combination (FDC) tablet.
Frequency Typically taken once daily; the schedule allows for the daily dose to be administered in two divided doses.
Timing (Food) May be taken with or without food, as the presence of food does not significantly impact absorption.

Use Context and Dosage Principles

The Enalapril-HCT combination product is generally not indicated for initial therapy for essential hypertension. Instead, its use is reserved for maintenance treatment in adult patients whose blood pressure has not been adequately controlled by the individual components administered separately. The standard daily dose is usually one tablet, available in set strengths such as 5 mg Enalapril / 12.5 mg HCT or 10 mg Enalapril / 25 mg HCT.

For proper administration, the tablet must be swallowed whole and should not be broken, crushed, or chewed. This requirement ensures the standardized delivery of the fixed ratio of ingredients. The medication is utilized as part of a long-term therapy plan, recognizing that achieving the full, optimal reduction in blood pressure may require several weeks of continued administration.

Population-Specific Use

The fixed combination is generally not recommended in severe renal insufficiency, specifically when creatinine clearance is le 30 mL/min. The safety and dosing requirements for use in pediatric patients have not been established in standard labeling.

Recent Clinical Evidence

Evidence for Essential Hypertension Management

The research for the fixed-dose combination of Enalapril and Hydrochlorothiazide primarily involves Randomized Controlled Trials (RCTs) and meta-analyses evaluating its use in adults whose blood pressure was not adequately controlled by a single medication. These studies monitor objective measurements, such as changes in systolic (SBP) and diastolic (DBP) blood pressure, and the percentage of participants reaching predefined goals. Studies reported patterns where measurements indicated a change in blood pressure when the combination was applied compared to single-drug treatments in those trials. This evidence contributes to understanding the short-term patterns of blood pressure control observed in the research landscape.


Long-Term Outcomes and Research Durations

Pivotal trials often involve short- to intermediate-term observation periods, typically up to 12 weeks, which provide context on initial blood pressure changes. Evidence related to outcomes observed in the fixed-dose combination over a long term, specifically concerning all-cause mortality or major cardiovascular events, remains limited in direct combination-specific trials. While data from the component drug classes were studied for long-term outcomes, large systematic reviews indicate that the specific long-term outcomes of the fixed combination on these vital measurements are not fully established and certainty remains low.


Evidence in Specific Patient Groups and Uncertainty

Research has included various adult groups, such as those with mild-to-moderate hypertension, older individuals (average age over 55 years), and patients with the comorbidity of Type II Diabetes. However, data for certain groups remain insufficient. The weight of evidence varies across different types of studies, and the long-term outcomes of the fixed-dose combination on the most critical clinical outcomes are still being researched. Research provides context but does not determine whether an individual will respond similarly.

Key Studies & References

  1. Enalapril - StatPearls - NCBI Bookshelf (Review of ACE inhibitor and combination use in hypertension/diabetes)

Frequently Asked Questions (FAQ)

Common questions about Enac plus Hexal (FAQ)


Q: Do you have to take Enac plus Hexal at a specific time of day?

A: Official information states that this medicine is typically taken once daily and can be administered with or without food. Since one of the ingredients is a diuretic (which increases urination), it is noted to recommend against taking it too close to bedtime to minimize the potential for increased nighttime urination.


Q: Is it normal to feel dizzy or lightheaded when first starting Enac plus Hexal?

A: Yes, regulatory documents note that dizziness and lightheadedness are common side effects, particularly when starting treatment or after the dose is adjusted. This feeling is often related to the initial effects on blood pressure. Regulatory guidance indicates that lightheadedness should be reported to a healthcare provider.


Q: What should be done if a potential side effect occurs?

A: Official patient advice emphasizes immediately reporting signs of serious side effects, such as angioedema (swelling of the face, lips, or tongue), and discontinuing the medicine until you can consult a professional. Other concerning symptoms, like severe lightheadedness or signs of infection, should also be reported promptly.


Q: Are there any documented cases of Enac plus Hexal being used for conditions other than high blood pressure?

A: According to regulatory documents, the official purpose of Enac plus Hexal is solely for the management of essential hypertension, which is chronic high blood pressure. This fixed-dose combination is generally reserved for maintenance treatment and is not intended for use as an initial therapy.


Q: What is the risk of low blood pressure (hypotension) with Enac plus Hexal?

A: Low blood pressure, or hypotension, is a documented common adverse reaction for this medication. Symptomatic hypotension, which can lead to lightheadedness or even fainting (syncope), may occur. This is noted to be more common in patients with existing volume depletion or during the initial phase of therapy.


Q: Are there different strengths of Enac plus Hexal tablets available?

A: Official product information confirms that the fixed-dose combination tablet is available in a limited number of set strengths. Examples of common strengths listed in prescribing information include 5 mg enalapril combined with 12.5 mg hydrochlorothiazide, and 10 mg enalapril with 25 mg hydrochlorothiazide.


Q: How does Enac plus Hexal differ from taking just the ACE inhibitor component?

A: Regulatory studies indicate that combining the two ingredients provides a blood pressure reduction that is roughly additive to the effects of the individual components. For this reason, the fixed-dose combination is generally used for maintenance treatment when an individual medicine alone has not adequately controlled blood pressure.


Q: How quickly can someone expect Enac plus Hexal to start working?

A: The onset of the blood pressure lowering effect begins approximately one hour after taking a single dose, reaching its maximum reduction between four and six hours. However, regulatory documents note that achieving the full, optimal long-term blood pressure control may require several weeks of continued daily administration.


Q: Does Enac plus Hexal help protect the kidneys?

A: The official indication for this combination medicine is the management of high blood pressure. The regulatory label does not include a broad claim that the drug provides kidney protection. Instead, official documents focus on the precautions required for use in patients who may have existing kidney problems.


Q: Can Enac plus Hexal be taken long-term?

A: Yes, this medication is designed and utilized as part of a long-term therapy plan for chronic high blood pressure. Clinical studies of the component drugs show that the blood pressure-lowering effects continue throughout extended periods of use.


Q: What happens if I miss a dose of Enac plus Hexal?

A: Regulatory patient information generally advises that if a dose is missed, the general guidance provided to patients is to skip that dose entirely. Official instructions state that a patient should not double the dose to compensate for the missed one.


Q: What happens if a person stops taking Enac plus Hexal suddenly?

A: According to official product documentation, the abrupt cessation (stopping suddenly) of the ACE inhibitor component has not been associated with a rapid rebound or sharp increase in blood pressure. However, discontinuing the medication requires consultation with a healthcare professional, as hypertension is a chronic condition that typically requires continuous management.


Q: Is it safe to drink alcohol in moderation while taking Enac plus Hexal?

A: Official safety information notes that alcohol can increase the risk of orthostatic hypotension, which is a form of low blood pressure that causes dizziness upon standing. Due to this documented interaction, regulatory information indicates that consuming alcohol may increase the potential for symptoms of low blood pressure.


Q: Are there known interactions between Enac plus Hexal and herbal supplements?

A: Regulatory guidance often points out that there is limited data to confirm the safety of using herbal remedies or supplements in combination with this medication. Official guidance recommends that individuals inform their healthcare professional about any supplements or herbal products they are taking.


Q: Can Enac plus Hexal be used by patients with diabetes?

A: Patients with Type II Diabetes have been included in clinical research for this combination. However, official warnings note a serious contraindication: the drug should not be used with Aliskiren in diabetic patients. Additionally, the medicine may affect blood sugar and potassium levels, potentially requiring adjustments to other antidiabetic medications.


Q: Is Enac plus Hexal appropriate for older adults (seniors)?

A: The use of this medicine is established in the adult population, which includes older adults. Regulatory information, however, advises caution in this age group due to the higher likelihood of reduced organ function. Dosage adjustments may be considered to account for these physiological differences.


Q: Can women of childbearing age use Enac plus Hexal?

A: Women of childbearing potential are advised in official warnings to be aware of the serious risk of fetal toxicity if they become pregnant while taking this drug. If pregnancy is detected, official product labeling indicates the medicine must be discontinued as soon as possible due to the risk of fetal toxicity.


Q: Has Enac plus Hexal been studied in people with liver problems?

A: Official safety information advises that the medicine is contraindicated (must not be used) in patients with severe hepatic impairment (severe liver problems). Furthermore, caution is advised for patients with any existing liver dysfunction, as minor changes in body salts or electrolytes could, in rare cases, precipitate a serious condition called hepatic coma.


Q: What kind of research has been done on the long-term effectiveness of Enac plus Hexal?

A: Research studies have typically focused on short- to intermediate-term observation periods, usually up to 12 weeks, to assess blood pressure changes. Official documents note that evidence specifically for the fixed-dose combination regarding crucial long-term outcomes, such as all-cause mortality or major cardiovascular events, is currently limited.


Q: Does research show that combining the two ingredients is better than taking them separately?

A: Research on the combination indicates that the blood pressure-lowering effect is approximately additive when compared to the effect of each component taken individually. This is why the combination product is officially reserved for patients whose blood pressure is not adequately controlled by the single components alone.


Q: What kind of tests might a doctor order while someone is taking Enac plus Hexal?

A: Official product information recommends that a patient’s renal function (kidney function), typically measured by serum creatinine, and serum electrolytes (such as potassium levels) should be monitored periodically. Monitoring of white blood cell counts may also be necessary for certain patient groups.


Q: Can taking Enac plus Hexal cause muscle cramps?

A: Yes, muscle cramps are included in the official list of possible adverse reactions documented for this medicine.


Q: Does Enac plus Hexal affect blood sugar levels?

A: Regulatory documents indicate that the medicine may have an effect on blood sugar (glucose) levels. For patients with diabetes, this effect may necessitate a dosage adjustment for their antidiabetic agents to maintain proper control.


Q: Is it true that this drug can affect potassium levels in the blood?

A: Yes, the official label confirms that the medicine can affect serum potassium levels. While the diuretic ingredient tends to lower potassium, the ACE inhibitor component often raises it. However, potassium should be monitored periodically.


Q: Is there a risk of sunlight sensitivity while taking Enac plus Hexal?

A: Since this medicine contains a thiazide diuretic (hydrochlorothiazide), regulatory guidance advises that there is a possibility of increased skin sensitivity to sunlight, also known as photosensitivity. Official guidance often includes caution regarding sun exposure, and the recommendation is to use appropriate sun protection.


Q: Is it necessary to maintain a low-salt diet while using Enac plus Hexal?

A: While the official drug label does not contain a specific instruction mandating a low-salt diet, it is important to note that dietary management is generally considered part of the overall treatment plan for hypertension.


Q: Why would a doctor switch a patient from a different blood pressure medicine to Enac plus Hexal?

A: According to regulatory documents, the primary reason a healthcare provider would prescribe this fixed-dose combination is if a patient’s blood pressure is not adequately controlled by a single medication alone. The combination provides an approximately additive benefit for blood pressure control.


Q: Where does Enac plus Hexal need to be stored?

A: Official storage instructions require the medicine to be kept at a controlled room temperature, generally between 15 C and 30 C (59 F and 86 F). The tablets must be kept in their original container, which should be tightly closed, and protected from both moisture and excessive heat.


Q: What are the known drug-drug interactions involving the diuretic part of Enac plus Hexal?

A: The hydrochlorothiazide component has documented interactions with several drug classes. These include lithium (which increases the risk of toxicity), NSAIDs (which can reduce the effectiveness of the diuretic), and cholestyramine/colestipol resins (which can decrease the absorption of the diuretic).


Q: Does the efficacy of Enac plus Hexal change over time?

A: Official studies on the component drugs indicate that the blood pressure-lowering effects continue during long-term therapy. While the full, optimal effect of the drug may take several weeks to achieve, its efficacy is expected to be maintained over time as part of a continuous treatment plan.


Q: Can Enac plus Hexal affect a person's ability to drive?

A: Regulatory warnings advise that the medication can cause dizziness or lightheadedness, especially when first standing up, due to its effect on blood pressure. Official warnings state that due to the risk of dizziness or lightheadedness, patients should not drive, operate machinery, or perform activities requiring alertness until they know how the medicine affects them.


Q: Do patients with kidney artery stenosis need special consideration for Enac plus Hexal?

A: Yes, official product information includes specific precautions for patients with bilateral or unilateral renal artery stenosis (a narrowing of the kidney arteries). The use of the ACE inhibitor component in these patients has been associated with changes in kidney function markers, such as increases in blood urea nitrogen. Renal function monitoring is advised during the initial weeks of treatment.


How should Enac plus Hexal be stored and disposed of?

Official Storage and Disposal Requirements

The storage of Enac plus Hexal (Enalapril maleate/Hydrochlorothiazide tablets) is defined by regulatory standards to maintain product integrity and safety. The medicine must be stored at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F), and must be protected from moisture and excessive heat.

Tablets should remain in the original container, which must be kept tightly closed. A mandatory safety requirement is to store the medicine out of the sight and reach of children.

For disposal, unused or expired medicine must be discarded according to official procedures, such as utilizing drug take-back programs. Regulatory guidance explicitly advises against flushing the tablets down the toilet or drain to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Enac plus Hexal found in:

A-Z Index: